Shailender Bhatia

Research interests

Publications

• Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology

  Journal of the National Comprehensive Cancer Network · 2022 · 10.6004/jnccn.2022.0020

• Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

  Clinical Cancer Research · 2022 · 10.1158/1078-0432.ccr-22-2235

• Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial

  Journal for ImmunoTherapy of Cancer · 2020 · 10.1136/jitc-2020-000674

• NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

  Journal of the National Comprehensive Cancer Network · 2020 · https://doi.org/10.6004/jnccn.2020.0012

• Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

  Cancer Cell · 2020 · 10.1016/j.ccell.2020.08.005

• Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial

  Journal of Clinical Oncology · 2020 · 10.1200/jco.20.00201

• Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study

  Annals of Oncology · 2019 · 10.1093/annonc/mdz176

• Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy

  Journal of Clinical Oncology · 2019 · 10.1200/jco.18.01896

• Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

  Journal of the National Comprehensive Cancer Network · 2019 · https://doi.org/10.6004/jnccn.2019.0013

• Age-Specific Incidence of Melanoma in the United States

  JAMA Dermatology · 2019 · 10.1001/jamadermatol.2019.3353

• Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA

  Nature Communications · 2018 · https://doi.org/10.1038/s41467-018-06300-3

• Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

  Journal for ImmunoTherapy of Cancer · 2018 · https://doi.org/10.1186/s40425-017-0310-x

• Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

  Clinical Cancer Research · 2018 · 10.1158/1078-0432.ccr-17-1922

• Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics

  Journal of the American Academy of Dermatology · 2017 · 10.1016/j.jaad.2017.10.028

• Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

  Cell · 2017 · https://doi.org/10.1016/j.cell.2017.09.028

• Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1709030

• Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy.

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2017.35.15_suppl.9520

• Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma

  Neuro-Oncology · 2016 · 10.1093/neuonc/now197

• Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30364-3

• Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma

  Cancer Medicine · 2016 · 10.1002/cam4.815

• PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1603702

• Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base

  JNCI Journal of the National Cancer Institute · 2016 · 10.1093/jnci/djw042

• Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

  New England Journal of Medicine · 2012 · https://doi.org/10.1056/nejmoa1200694

• Systemic Immune Suppression Predicts Diminished Merkel Cell Carcinoma–Specific Survival Independent of Stage

  Journal of Investigative Dermatology · 2012 · 10.1038/jid.2012.388

• Treatment of metastatic melanoma: an overview.

  PubMed · 2009

Current projects

No projects listed.